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(J Thorac Oncol. 2007; suppl. 2: S49–S50)With approximately 1.3 million cases and 1.1 million deaths per year worldwide, lungcancer represents a very common and highly lethal cancer.1 Certainly, the ultimate
goal of managing this disease is prevention, and we have the advantage that the primary
causative factor is identified, well known, and above all, modifiable. In parts of the world
such as the United States and northern and western Europe, the efforts of education and
smoking cessation programs have had an impact on the incidence of smoking with a
resulting decrease in the incidence of lung cancer. Lung cancer is far from eradicated, and
trends of decreasing incidence in women lag behind those of men, ensuring decades more
of unacceptably high incidence rates. In other geographical areas, however, such as
southern and eastern Europe, the incidence continues to rise even in men.1 We are thus
faced with the continuing need to develop better management of this cancer.
By far the most common type of lung cancer is non-small cell lung cancer (NSCLC),
and this supplement was created to apprise the practising clinician of the latest research on
this disease. It is, however, no longer sufficient simply to stay abreast of new developments
in the treatment of NSCLC. On the contrary, we must advance a step further by changing
our way of thinking about the disease and embrace new treatment paradigms. This
supplement to the Journal of Thoracic Oncology reviews the recent advances in clinical
and translational research and perspectives on the treatment of NSCLC. These articles
represent, in part, presentations of key thought leaders in lung cancer research and
treatment that were given during the Interactive Lung Cancer Conference 2006 in Lisbon,
Portugal. This unique international conference provided the opportunity for oncologists to
engage in discussions about their experiences with treating NSCLC around the globe. You
will find that the authors and investigators reach beyond the current standards of care, and
challenge the reader to accept the possibility of incorporating new treatment paradigms as
research advances and new technologies become available.
To make rational treatment choices based on available data, clinical trial endpoints
must be critically examined, particularly in the context of their practicality and
applicability to daily practice. Richard Gralla and Frank Griesinger provide a critical
interpretation of clinical trial endpoints used in recent studies and present compelling data
supporting the evaluation of quality of life measures, especially if there is a gain in
survival. They further argue that measuring quality of life must not remain the sole domain
of clinical trials, but should be incorporated into routine day-to-day clinical practice.
The underlying biology of NSCLC tumors is of key interest in order to identify
patients who might respond to specific therapy and to make a proper selection of patients
for currently available molecularly targeted agents. Frances Shepherd and Rafael Rosell
review clinical data with targeted agents, particularly those that target the epidermal
growth factor receptor (EGFR). The story on EGFR gene mutations, gene amplificationformation BV. Unauthorized reproduction of this article is prohibited.
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There is still a great deal of controversy as to their prognostic
versus predictive value when considering treatment with
EGFR tyrosine kinase inhibitors. EGFR gene mutations
have been linked to very high response rates (60–90%) in
NSCLC patients, but the correlation with survival has not
been firmly established. On the other hand, gene amplifica-
tion, defined as a gene-to-chromosome 7 ratio greater than 2,
is noted in approximately 10% of all cases of NSCLC
(detected by fluorescence in situ hybridization). An
additional 20% of NSCLC tumors have more than four
copies of the gene in 40% or more of cells (high polysomy),
and appear to have a survival benefit from EGFR tyrosine
kinase inhibitor therapy, which suggests a prognostic
impact. These data are from retrospective analysis, and
until such results are available from large prospective
clinical trials, these markers should not be routinely
incorporated into community practice.
The overall management of patients with NSCLC is
highly dependent on the stage of disease at presentation.
Despite several practice guidelines available to clinicians,
the choice of staging modalities relies on a variety of factors,
including the availability of positron emission tomography–
computed tomography and endoscopic ultrasonography–
fine needle aspiration. These may enhance the accuracy
of pre or post-therapy mediastinal staging, and as their
availability widens they are likely to become part of
standard treatment paradigms. Thoracic surgeons still do not
prefer second mediastinoscopy post therapy. Edward Kim
and Lionel Bosque´e review the data involving the incor-
poration of newer staging techniques that have the potentialCopyright © Adis Data Information BV. Una
S50to improve patient care. Will the present technology and
expertise identify appropriate candidates for more aggres-
sive therapy and at the same time avoid futile surgical
intervention?
The treatment of locally advanced NSCLC presents by
far the greatest challenge. Stage III disease encompasses a
heterogeneous group of tumors. Separating potentially resec-
table disease from categorically unresectable disease has
been a challenge. James Rigas and Karen Kelly review the
current evidence supporting chemotherapy treatment as
neoadjuvant therapy in resectable disease and as part of com-
bined modality regimens in unresectable stage III NSCLC.
Emerging data on the role of consolidation with single agent
docetaxel compared with other regimens are reviewed.
Finally, as newer agents have been explored for
use in advanced NSCLC, the choice of chemotherapy
regimens has become more complex. Giorgio Scagliotti
reviews the results of randomized trials comparing a
docetaxel-based or vinca alkaloid-based regimen as first-
line treatment of advanced NSCLC. In addition, clinical
trials of first-line cisplatin-based doublets utilizing doce-
taxel, paclitaxel, vinorelbine, vindesine, and gemcitabine
are reviewed.
I hope that this supplement of the Journal of Thoracic
Oncology provides valuable information as you treat pa-
tients today and prompts thoughtful consideration for the
development of future treatment strategies.
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